Matches in Wikidata for { <http://www.wikidata.org/entity/Q66400493> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q66400493 description "clinical trial" @default.
- Q66400493 description "ensayu clínicu" @default.
- Q66400493 description "klinisch onderzoek" @default.
- Q66400493 description "клінічне випробування" @default.
- Q66400493 name "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus" @default.
- Q66400493 name "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol" @default.
- Q66400493 type Item @default.
- Q66400493 label "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus" @default.
- Q66400493 label "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol" @default.
- Q66400493 prefLabel "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus" @default.
- Q66400493 prefLabel "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol" @default.
- Q66400493 P1132 Q66400493-5E806831-AD95-4C10-8DC3-6B00DC83DDBA @default.
- Q66400493 P1476 Q66400493-AEAA38D8-1DB9-4A5E-A93A-9252DA56F14A @default.
- Q66400493 P17 Q66400493-09FC9C38-0076-4B25-B49F-55BD7E4A508F @default.
- Q66400493 P17 Q66400493-45578C74-8D58-4CDF-A5AB-D1610BCB75E1 @default.
- Q66400493 P17 Q66400493-46AF66D0-C0AD-46A2-9972-B82651BC33CA @default.
- Q66400493 P17 Q66400493-508D67DA-6F2D-420D-BB08-EED3D6177115 @default.
- Q66400493 P17 Q66400493-6E9F0E34-B5D7-4C79-90E5-4D3484FA1CC5 @default.
- Q66400493 P17 Q66400493-9607E173-491C-4642-BF75-96A474438D32 @default.
- Q66400493 P17 Q66400493-9F2E3D05-DDE0-4415-A010-C3E567CD2979 @default.
- Q66400493 P17 Q66400493-A23A5A10-7E38-4CC1-BA87-1077473BE8A5 @default.
- Q66400493 P17 Q66400493-A4B8C839-04B9-4511-99DA-EA4968E063EA @default.
- Q66400493 P17 Q66400493-A658CA82-F9A0-4AB5-ADDF-60C9C086A51F @default.
- Q66400493 P17 Q66400493-BECF4337-4488-4D1F-BA99-C7A85DE1243E @default.
- Q66400493 P17 Q66400493-FE7C56D6-C23A-48AE-8043-5CB4F57A69B5 @default.
- Q66400493 P2899 Q66400493-7F6A3700-7354-485E-889E-53034884046C @default.
- Q66400493 P3098 Q66400493-A6A9845B-019E-40B4-97C9-EACAD3F1E29E @default.
- Q66400493 P31 Q66400493-781A1054-1837-491C-84EB-CBB6ED7D1D66 @default.
- Q66400493 P580 Q66400493-24B33F46-90F2-4757-A8BE-49AC2C314511 @default.
- Q66400493 P582 Q66400493-B21C3769-EFEC-473C-81DE-DDA435B7B056 @default.
- Q66400493 P6099 Q66400493-3D1BB901-067A-4553-8AEB-57C02816772B @default.
- Q66400493 P8363 Q66400493-1DE85037-C769-4262-A2A2-FC22D17DAABF @default.
- Q66400493 P1132 "+182" @default.
- Q66400493 P1476 "A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus" @default.
- Q66400493 P17 Q183 @default.
- Q66400493 P17 Q212 @default.
- Q66400493 P17 Q218 @default.
- Q66400493 P17 Q219 @default.
- Q66400493 P17 Q28 @default.
- Q66400493 P17 Q29 @default.
- Q66400493 P17 Q298 @default.
- Q66400493 P17 Q30 @default.
- Q66400493 P17 Q36 @default.
- Q66400493 P17 Q419 @default.
- Q66400493 P17 Q739 @default.
- Q66400493 P17 Q96 @default.
- Q66400493 P2899 "+18" @default.
- Q66400493 P3098 "NCT02804763" @default.
- Q66400493 P31 Q30612 @default.
- Q66400493 P580 "2016-06-02T00:00:00Z" @default.
- Q66400493 P582 "2018-05-31T00:00:00Z" @default.
- Q66400493 P6099 Q42824440 @default.
- Q66400493 P8363 Q78089383 @default.